The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy
Open accessAbstract
Background Hypertrophic cardiomyopathy is a genetic disease characterized by cardiac hypertrophy, myocyte disarray, interstitial fibrosis, and left ventricular (LV) dysfunction. We have proposed that hypertrophy and fibrosis, the major determinants of mortality and morbidity, are potentially reversible. We tested this hypothesis in β-myosin heavy chain–Q 403 transgenic rabbits. Methods and Results We randomized 24 β-myosin heavy chain–Q 403 rabbits to treatment with either a placebo or simvastatin (5 mg · kg −1 · d −1 ) for 12 weeks and included 12 nontransgenic controls. We performed 2D and Doppler echocardiography and tissue Doppler imaging before and after treatment. Demographic data were similar among the groups. Baseline mean LV mass and interventricular septal thickness in nontransgenic, placebo, and simvastatin groups were 3.9±0.7, 6.2±2.0, and 7.5±2.1 g ( P <0.001) and 2.2±0.2, 3.1±0.5, and 3.3±0.5 mm ( P =0.002), respectively. Simvastatin reduced LV mass by 37%, interventricular septal thickness by 21%, and posterior wall thickness by 13%. Doppler indices of LV filling pressure were improved. Collagen volume fraction was reduced by 44% ( P <0.001). Disarray was unchanged. Levels of activated extracellular signal-regulated kinase (ERK) 1/2 were increased in the placebo group and were less than normal in the simvastatin group. Levels of activated and total p38, Jun N-terminal kinase, p70S6 kinase, Ras, Rac, and RhoA and the membrane association of Ras, RhoA, and Rac1 were unchanged. Conclusions Simvastatin induced the regression of hypertrophy and fibrosis, improved cardiac function, and reduced ERK1/2 activity in the β-myosin heavy chain–Q 403 rabbits. These findings highlight the need for clinical trials to determine the effects of simvastatin on cardiac hypertrophy, fibrosis, and dysfunction in humans with hypertrophic cardiomyopathy and heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudden Death in Young Competitive Athletes: Clinical, Demographic, and Pathological Profiles
Maron, B. J. (1996) · JAMA · doi:10.1001/jama.1996.03540030033028 · Cited by 1,693
Organization and regulation of mitogen-activated protein kinase signaling pathways
Garrington, T. P., & Johnson, G. L. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80028-3 · Cited by 1,275
Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death
Haider, A. W., Larson, M. G., Benjamin, E. J., & Levy, D. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00407-0 · Cited by 800
Watkins, H., Rosenzweig, A., Hwang, D.-S., Levi, T., McKenna, W., Seidman, C. E., & Seidman, J. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261703 · Cited by 747
Nagueh, S. F., Bachinski, L. L., Meyer, D., Hill, R., Zoghbi, W. A., Tam, J. W., Quiñones, M. A., Roberts, R., & Marian, A. J. (2001) · Circulation · doi:10.1161/01.cir.104.2.128 · Cited by 616
Self-citationNagueh, S. F., Lakkis, N. M., Middleton, K. J., Spencer, W. H., Zoghbi, W. A., & Quiñones, M. A. (1999) · Circulation · doi:10.1161/01.cir.99.2.254 · Cited by 530
Self-citationSugden, P. H., & Clerk, A. (1998) · Circulation Research · doi:10.1161/01.res.83.4.345 · Cited by 513
The Molecular Genetic Basis for Hypertrophic Cardiomyopathy
Marian, A. J., & Roberts, R. (2001) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2001.1340 · Cited by 438
Self-citationShirani, J., Pick, R., Roberts, W. C., & Maron, B. J. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00492-1 · Cited by 408
Guijarro, C., Blanco-Colio, L. M., Ortego, M., Alonso, C., Ortiz, A., Plaza, J. J., Díaz, C., Hernández, G., & Egido, J. (1998) · Circulation Research · doi:10.1161/01.res.83.5.490 · Cited by 390
Lim, D.-S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., Roberts, R., & Marian, A. J. (2001) · Circulation · doi:10.1161/01.cir.103.6.789 · Cited by 386
Self-citationGrünler, J., Ericsson, J., & Dallner, G. (1994) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)90200-3 · Cited by 261
Pre-arrest morbidity and other correlates of survival after in-hospital cardiopulmonary arrest
George, A. L., Folk, B. P., Crecelius, P. L., & Campbell, W. B. (1989) · The American Journal of Medicine · doi:10.1016/s0002-9343(89)80479-6 · Cited by 253
Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy
Marian, A. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06187-5 · Cited by 235
Self-citationZou, Y., Komuro, I., Yamazaki, T., Aikawa, R., Kudoh, S., Shiojima, I., Hiroi, Y., Mizuno, T., & Yazaki, Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33592 · Cited by 211
Hori, Y., Kikuchi, A., Isomura, M., Katayama, M., Miura, Y., Fujioka, H., Kaibuchi, K., & Takai, Y. (1991) · PubMed · Cited by 197
Hernández-Perera, O., Pérez-Sala, D., Soria, E., & Lamas, S. (2000) · Circulation Research · doi:10.1161/01.res.87.7.616 · Cited by 188
A transgenic rabbit model for human hypertrophic cardiomyopathy
Marian, A. J., Wu, Y., Lim, D.-S., McCluggage, M., Youker, K., Yu, Q.-T., Brugada, R., DeMayo, F., Quinones, M., & Roberts, R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7956 · Cited by 181
Self-citationSpirito, P., & Maron, B. J. (1990) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(90)92820-r · Cited by 175
Nagueh, S. F., Kopelen, H. A., Lim, D.-S., Zoghbi, W. A., Quiñones, M. A., Roberts, R., & Marian, A. J. (2000) · Circulation · doi:10.1161/01.cir.102.12.1346 · Cited by 171
Self-citationGerson, R. J., MacDonald, J. S., ALBERTS, A. W., Kornbrust, D. J., Majka, J. A., Stubbs, R. J., & Bokelman, D. L. (1989) · The American Journal of Medicine · doi:10.1016/s0002-9343(89)80596-0 · Cited by 136
Luo, J., Zhang, W., Zhang, G., Guan, J., & Chen, X. (1999) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.1999.03165.x · Cited by 116
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells
Oi, S., Haneda, T., Osaki, J., Kashiwagi, Y., Nakamura, Y., Kawabe, J.-I., & Kikuchi, K. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00282-4 · Cited by 111
Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis
Assayag, P. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00073-4 · Cited by 100
Park, G.-H., & Galper, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11525 · Cited by 62
Activation of extracellular-regulated kinases by normal and mutant EGF receptors
Lorimer, I. A. J., & Lavictoire, S. J. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(00)00129-4 · Cited by 41
Cited by
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e2bd · Cited by 2,104
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
Self-citation
Metadata
- Authors
- Patel, R., Nagueh, S. F., Tsybouleva, N., Abdellatif, M., Lutucuta, S., Kopelen, H. A., Quinones, M. A., Zoghbi, W. A., Entman, M. L., Roberts, R., & Marian, A. J.
- Venue
- Circulation
- Published
- 2001-07-17
- Volume
- 104
- Issue
- 3
- Pages
- 317-324
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2120194464
- Cited by
- 357
- References
- 26
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.